Skip to main content

Dr. Warren R. Abel, MD

Pulmonology (Pulmonary Disease Physician)

  • Medicare participating

At a glance

Years since graduation
41
In the NPI registry since
2006
Medicare patients seen, 2024
375

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1985Medical school: University of South Florida College of Medicine
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Pulmonary Disease Physician primary
    FL license ME62909
  • Critical Care Medicine (Internal Medicine) Physician
    FL license ME62909

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Pulmonology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
375
Services billed
1,055
Patients’ average age
77
Most frequent Medicare services, 2023
ServiceTimesPatients
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes462175
Established patient office or other outpatient visit, 30-39 minutes374205
Critical care, first 30-74 minutes17481
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes6462
Test to examine how well the lungs exchange gases5857
Test to measure expiratory airflow and volume changes before and after medication administration5857
Test to determine lung volumes using sensors5756
New patient office or other outpatient visit, 60-74 minutes2222
Established patient office or other outpatient visit, 40-54 minutes2119
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes1919

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 24 companies reported 92 payments worth $2,278 in total to this clinician.

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Aug 15, 2025Insmed, Inc.
Aug 15, 2025
Education
in-kind
$17.38

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Florida →

Industry-funded research

Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $149,536 in research payments for these studies, mostly to the institutions running them.

  • A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
    E.r. Squibb & Sons, L.l.c.
  • The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic …
    AstraZeneca Pharmaceuticals LP
  • A prospective, real-world, interventional study to evaluate the effect
    GlaxoSmithKline, LLC.
  • Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
    Sanofi US Services Inc. · Completed · NCT04701983
  • A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
    E.r. Squibb & Sons, L.l.c.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Pulmonology clinicians in St Petersburg

Sources

NPI registry (CMS NPPES, November 2026; record last updated January 15, 2026), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1912939067. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.